Cytosorbents (CTSO) Operating Expenses (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Operating Expenses data on file, last reported at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 9.12% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $40.3 million (up 1.04% YoY), and the FY2025 full-year result was $41.2 million, changed 0.24% from the prior year.
• Operating Expenses for Q1 2026 stood at $9.2 million, down from $11.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $14.6 million in Q4 2023 and bottomed at $9.2 million in Q1 2026.
• The 5-year median for Operating Expenses is $11.5 million (2024), against an average of $11.6 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 32.76%; it then slumped 34.1% in 2024.
• A 5-year view of Operating Expenses shows it stood at $12.1 million in 2022, then rose by 20.88% to $14.6 million in 2023, then plunged by 34.1% to $9.6 million in 2024, then advanced by 15.95% to $11.2 million in 2025, then decreased by 18.01% to $9.2 million in 2026.
• The last three Operating Expenses figures came in at $9.2 million (Q1 2026), $11.2 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.

Peer Comparison